We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 03, 2019

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
J. Clin. Oncol 2019 Oct 14;[EPub Ahead of Print], DP Modest, UM Martens, J Riera-Knorrenschild, J Greeve, A Florschütz, S Wessendorf, T Ettrich, S Kanzler, D Nörenberg, J Ricke, M Seidensticker, S Held, P Buechner-Steudel, J Atzpodien, V Heinemann, T Seufferlein, A Tannapfel, AC Reinacher-Schick, M Geissler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading